Praxis precision medicines provides updates on clinical stage pediatric epilepsy programs

Boston, sept. 07, 2022 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced the plan to start the prax-222 embrave clinical study for the treatment of pediatric patients with early-seizure-onset scn2a developmental and epileptic encephalopathy (dee), after the u.s. food and drug administration (fda) cleared the investigational new drug (ind) application for the initial dose cohort. following collection of the safety and efficacy data from the first cohort of patients in the embrave study, the data will be evaluated and submitted to the fda to seek authorization for further dose escalation.
PRAX Ratings Summary
PRAX Quant Ranking